Entrada Therapeutics Analyst Ratings
TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20
Entrada Therapeutics Analyst Ratings
Positive Prospects for Entrada Therapeutics Despite FDA Hold: An Analyst's Buy Rating Justification
Entrada Therapeutics' Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Rating
TD Cowen Remains a Buy on Entrada Therapeutics Inc (TRDA)
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)
Entrada Therapeutics Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics Inc (TRDA) Gets a Hold From Goldman Sachs
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV)
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Inc (TRDA) Receives a Buy From H.C. Wainwright
No Data